Whatever the reason, I’m more reflective these days than ever. Late spring and early summer in Philadelphia was a time for more reflection as our city hosted both the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and The Bio International Convention (BIO) 2015 meeting.
Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
After more than 2 centuries of work, we now understand more about the cellular biology of rheumatoid arthritis, but the underlying cause of the disease remains elusive.
Closing Gaps in Health Plan Performance with Stakeholder Collaboration
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD
Although varicose veins are considered by some policymakers to primarily be an aesthetic concern, varicosities and their resulting sequelae are primary contributors to the morbidity associated with chronic venous diseases.
A Teachable Moment in Health Benefits Design
Margaret K. Pasqule, PhD, Anthony M. Louder, PhD, RPh, Raymond Y. Cheung, PhD, Andrew T. Reiners, MD, Robert J. Sanchez, PhD, Veerainder Goli, MD, MBA, DFAPA, Jack Mardekian, PhD
From 1999 to 2008, the utilization rate of total knee replacement procedures in the United States more than doubled for the overall population, and tripled for individuals aged 45 to 64 years.
Knee and Hip Pain: Rewarding Optimal Long-Term Management
Results 1 - 5 of 5